Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
Authors:
Top Cited Papers
- 5 October 2011
- journal article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 108 (46) , 18843-18848
Abstract
Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene that impair the function of CFTR, an epithelial chloride channel required for proper function of the lung, pancreas, and other organs. Most patients with CF carry the F508delCFTRmutation, which causes defective CFTR protein folding and processing in the endoplasmic reticulum, resulting in minimal amounts of CFTR at the cell surface. One strategy to treat these patients is to correct the processing of F508del-CFTR with small molecules. Here we describe the in vitro pharmacology of VX-809, a CFTR corrector that was advanced into clinical development for the treatment of CF. In cultured human bronchial epithelial cells isolated from patients with CF homozygous for F508del, VX-809 improved F508del-CFTR processing in the endoplasmic reticulum and enhanced chloride secretion to approximately 14% of non-CF human bronchial epithelial cells (EC50, 81 ± 19 nM), a level associated with mild CF in patients with less disruptiveCFTRmutations. F508del-CFTR corrected by VX-809 exhibited biochemical and functional characteristics similar to normal CFTR, including biochemical susceptibility to proteolysis, residence time in the plasma membrane, and single-channel open probability. VX-809 was more efficacious and selective for CFTR than previously reported CFTR correctors. VX-809 represents a class of CFTR corrector that specifically addresses the underlying processing defect in F508del-CFTR.Keywords
This publication has 45 references indexed in Scilit:
- Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTRMutationNew England Journal of Medicine, 2010
- Peripheral Protein Quality Control Removes Unfolded CFTR from the Plasma MembraneScience, 2010
- Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosisNature Chemical Biology, 2009
- Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770Proceedings of the National Academy of Sciences, 2009
- High treatment burden in adults with cystic fibrosis: Challenges to disease self-managementJournal of Cystic Fibrosis, 2009
- Guidelines for Diagnosis of Cystic Fibrosis in Newborns through Older Adults: Cystic Fibrosis Foundation Consensus ReportThe Journal of Pediatrics, 2008
- Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practiceJournal of Cystic Fibrosis, 2008
- Phenylalanine-508 mediates a cytoplasmic–membrane domain contact in the CFTR 3D structure crucial to assembly and channel functionProceedings of the National Academy of Sciences, 2008
- Chloride channels as drug targetsNature Reviews Drug Discovery, 2008
- Additive effect of multiple pharmacological chaperones on maturation of CFTR processing mutantsBiochemical Journal, 2007